Amgen Inc., Plaintiff-Cross v. Hoechst Marion Roussel, Inc. (Now Known as Aventis Pharmaceuticals, Inc.) and Transkaryotic Therapies, Inc.

U.S. Court of Appeals, Federal Circuit · Decided 2003-03-03

Cited by 332 later decision(s) in our corpus · see the citation network in Lexace

From the opinion

MICHEL, Circuit Judge. Plaintiff-Cross Appellant Amgen Inc. (“Amgen”) is the owner of numerous patents directed to the production of erythro-poietin (“EPO”), a naturally occurring hormone that controls the formation of red blood cells in bone marrow. Amgen markets and sells EPOGEN®, a highly successful commercial embodiment of the patented erythropoietin. Seeking to impede defendants-appellants Hoechst Marion Roussel, Inc.…

Read the full opinion (source) ↗

Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Citation figures are counts of later citing opinions in our corpus and may be incomplete; always read and Shepardize the full opinion before relying on it.